JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer

JOHNSON & JOHNSON

2023-Q2 EPS reported $1.93 revenue$50,276,000,000

Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.
GAAP diluted EPS $1.96 (+8.9%); adjusted diluted EPS $2.80 (+8.1%).
FY 2023 adjusted operational sales ex-COVID vaccine and adjusted operational EPS guidance midpoints raised.
Board authorizes Kenvue share split-off via exchange offer as next step in separation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.89

JOHNSON & JOHNSON reported second quarter ended July 2, 2023 results: revenue $25.5 Billion, net income $5,144, EPS $1.96. Guidance raised.

Period: second quarter ended July 2, 2023
Revenue: $25.5 Billion
Net income: $5,144
EPS: $1.96
Guidance: raised
Result: reported results

Exact text from the filing

the second quarter ended July 2, 2023. --- EX-99.1 (EX-99.1) --- JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS: • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* • Earnings per share (EPS) of $1.96 increasing

View on SEC.gov

Browse all earnings releases →

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0000200406-23-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.